Liver cancer, unfortunately, is the sixth most common cancer and the third most frequent cause of cancer-related death globally.
AGC Biologics hit with 483 for poor discrepancy investigation practices, quality control issues at Washington site
CDMO ACG Biologics received an FDA 483 letter, published on the FDA website this week, noting one of its sites failed to conduct proper investigations
February 2, 2024